ADC Therapeutics Restructures to Focus on Key AssetsADC TherapeuticsADC Therapeutics is closing its UK research site and reducing its workforce by 30% to focus on its approved cancer drug Zynlonta and a prostate-specific membrane antigen ADC, discontinuing several early-stage programs.
EN
Agricultural News
Food News
Industrial News
Cosmetic News
Pharmaceutical News
Science News
